Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B-cell Lymphoma with 17p Deletion
Double-expressor diffuse large B-cell lymphoma (DLBCL) with 17p deletion is an aggressive and refractory disease. Immune checkpoint blockade and epigenetic drugs have been widely used, but the efficacy of different combined applications varied. We report a case with “double-expressor” DLBCL treated...
Saved in:
Main Authors: | Runhui Zheng, Xiaobo Chen, Chunyan Wang, Pengfei Qin, Huo Tan, Xiaodan Luo |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2020/8879448 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Acetylation and Histone Deacetylase Inhibitors in Cancer
by: Madeleine S. Q. Kortenhorst, et al.
Published: (2006-01-01) -
Histone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming
by: Androniki Kretsovali, et al.
Published: (2012-01-01) -
Histone Deacetylase Inhibitors: Synthesis of Tetrapeptide Analogue SAHA/TPX
by: Lynda Ekou, et al.
Published: (2011-01-01) -
Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives
by: Hua Zhang, et al.
Published: (2015-01-01) -
Comparison of Different Histone Deacetylase Inhibitors in Attenuating Inflammatory Pain in Rats
by: Yu Mao, et al.
Published: (2019-01-01)